According to information, on Monday, Moderna (MRNA.US) shares surged, rising over 7% to $27.85 by the time of reporting. The company presented the latest data from its mRNA vaccine pipeline at the IDWeek 2025 conference, including clinical results for the seasonal flu vaccine mRNA-1010 and the combination vaccine mRNA-1018. The data showed that both vaccines elicited rapid and robust immune responses in adult subjects, with no significant safety issues observed.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.